Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
暂无分享,去创建一个
F. Uckun | C. Cogle | E. Wang | P. Patel | P. Shami | E. Cull | J. Watts | A. Mims | Anoush Shahidzadeh | Cynthia Lee | T. Lin
[1] F. Uckun,et al. Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436 , 2021, Cancers.
[2] F. Uckun,et al. A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome , 2021, Cancers.
[3] Tamer Othman,et al. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. , 2021, Future Oncology.
[4] M. Konopleva,et al. Immunotherapy in Acute Myeloid Leukemia: Where We Stand , 2021, Frontiers in Oncology.
[5] N. Daver,et al. T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments , 2021, Leukemia.
[6] M. Minden,et al. Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production , 2021, Blood.
[7] M. Minden,et al. Venetoclax enhances T cell-mediated anti-leukemic activity by increasing ROS production. , 2021, Blood.
[8] J. Gabrilove,et al. Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies , 2021, HemaSphere.
[9] A. Almasan,et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance , 2020, Cell Death & Disease.
[10] P. Vyas,et al. New directions for emerging therapies in acute myeloid leukemia: the next chapter , 2020, Blood Cancer Journal.
[11] S. Rutella,et al. Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. , 2020, Blood.
[12] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[13] W. Blum,et al. Treating acute myeloid leukemia in the modern era: A primer , 2020, Cancer.
[14] David Lara-Astiaso,et al. Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma. , 2020, Blood.
[15] M. Konopleva,et al. Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges. , 2020, Cancer discovery.
[16] F. Uckun,et al. A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia , 2019, Cancers.
[17] C. Dinardo,et al. How I treat acute myeloid leukemia in the era of new drugs. , 2019, Blood.
[18] D. Jablonski,et al. Abstract LB-199: APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity with limited cytokine release, is well tolerated in repeat dose toxicology studies in cynomolgus macaques , 2019, Immunology.
[19] W. Blum,et al. Progress in the problem of relapsed or refractory acute myeloid leukemia , 2019, Current opinion in hematology.
[20] F. Ferrara,et al. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia , 2019, Cancers.
[21] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[22] Austin E. Gillen,et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia , 2018, Nature Medicine.
[23] A. D’Alessandro,et al. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. , 2018, Cancer cell.
[24] M. Konopleva,et al. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.
[25] A. Letai,et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[26] R. Schlenk,et al. Relapsed/refractory acute myeloid leukemia: any progress? , 2017, Current opinion in oncology.
[27] A. Al-Mawali,et al. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection , 2017, Acta Haematologica.
[28] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[29] James M Wilson,et al. The Next Chapter. , 2015, Human gene therapy.
[30] J. Dipersio,et al. Targeting CD123 In Leukemic Stem Cells Using Dual Affinity Re-Targeting Molecules (DARTs®) , 2013 .
[31] John M. Ashton,et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.
[32] S. Jang,et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia , 2012, Annals of Hematology.
[33] J. Tamburini,et al. High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.
[34] J. Dick,et al. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. , 2009, Cell stem cell.
[35] E. Coccia,et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. , 2002, Blood.